DME Treatment Study

Active Clinical Trials // Feb 12 2018

A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema (Five-year follow up)

Sponsor(s): Diabetic Retinopathy Clinical Research Network

Principal Investigator: Justin Gottlieb, MD

Study Coordinator: Kris Dietzman

Study Objectives:

The primary objective is to perform descriptive analyses for the following:

  • Visual acuity outcomes at 5 years 2167
  • DME outcomes at 5 years 2168
  • Types of DME treatments used since 2 year study visit 2169
  • Frequency of DME agents used since 2 year study visit 2170
  • Treatments for diabetic retinopathy since 2 year study visit 2171
  • Diabetic retinopathy outcomes at 5 years 2172
  • APTC events occurring in participants since 2-year study visit

Eligibility Criteria:

Study eyes of previously randomized participants in Protocol T

Sample Size:

Sample size is expected to be between 400 and 425 participants

Visit Schedule:

Each willing participant will have one follow-up study visit, approximately 5 years (±6 months) after original randomization.


For more information, contact Kris Dietzman 608-263-9035